UBS reaffirms its 'buy' recommendation on Sanofi, with the target price maintained at 110 euros, representing a 26% upside potential for the stock, as the broker looks back on the results unveiled last week by the French healthcare giant.

The 2024 forecast of no leverage on sales was reiterated, but in the longer term, sales growth of 5.8% should translate into EPS growth of 9.4% over the long term, so the share remains attractive', he believes.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.